Knight Therapeutics Inc. (TSX: GUD)
Market Cap | 579.87M |
Revenue (ttm) | 332.21M |
Net Income (ttm) | -17.44M |
Shares Out | 101.28M |
EPS (ttm) | -0.18 |
PE Ratio | n/a |
Forward PE | 263.16 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 46,215 |
Open | 5.65 |
Previous Close | 5.67 |
Day's Range | n/a |
52-Week Range | 4.35 - 6.22 |
Beta | 0.48 |
Analysts | n/a |
Price Target | 7.19 (+25.7%) |
Earnings Date | Aug 8, 2024 |
About Knight Therapeutics
Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Ne... [Read more]
Financial Performance
In 2023, GUD's revenue was 328.20 million, an increase of 11.80% compared to the previous year's 293.56 million. Losses were -16.84 million, -43.68% less than in 2022.
Financial StatementsNews
Knight Therapeutics reports Q1 results
![](https://cdn.snapi.dev/images/v1/q/u/press4-2420569.jpg)
Knight Therapeutics Reports First Quarter 2024 Results
MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial re...
![](https://cdn.snapi.dev/images/v1/c/i/press11-2420577.jpg)
Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for JORNAY PM® for Canada and Latin America
MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an exclusi...
![](https://cdn.snapi.dev/images/v1/8/z/press17-2419680.jpg)
Knight Therapeutics Inc. announces voting results from the Annual General Meeting
MONTREAL, May 08, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Corporation") a leading pan-American (ex-US) specialty pharmaceutical company, announced today the votin...
Notice of Knight Therapeutics’ First Quarter 2024 Results Conference Call
MONTREAL, May 02, 2024 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2024 financia...
![](https://cdn.snapi.dev/images/v1/1/g/conf11-2405684.jpg)
Notice of Knight Therapeutics' First Quarter 2024 Results Conference Call
MONTREAL, May 02, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2024 financi...
Knight Therapeutics Inc. (KHTRF) Q4 2023 Earnings Call Transcript
Knight Therapeutics GAAP EPS of -C$0.23, revenue of C$74.2M
![](https://cdn.snapi.dev/images/v1/p/s/press14-2334949.jpg)
Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results
MONTREAL, March 21, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial ...
Notice of Knight Therapeutics’ Fourth Quarter and Year End 2023 Results Conference Call
MONTREAL, March 14, 2024 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year e...
![](https://cdn.snapi.dev/images/v1/o/u/conf14-2324002.jpg)
Notice of Knight Therapeutics' Fourth Quarter and Year End 2023 Results Conference Call
MONTREAL, March 14, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year ...
Knight Therapeutics launches Minjuvi in Brazil
![](https://cdn.snapi.dev/images/v1/t/4/press17-2298152.jpg)
Knight Therapeutics Inc. Celebrates its First Decade of Success
MONTREAL, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it is marking its 10-year ann...
![](https://cdn.snapi.dev/images/v1/d/d/press2-2287326.jpg)
Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil
MONTREAL, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, Unit...
![](https://cdn.snapi.dev/images/v1/m/f/press9-2261664.jpg)
Knight Therapeutics Announces Launch of Bijuva® in Canada
MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a Pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of BIJUVA® (estradiol ...
Amneal Pharma inks licensing pact with Knight Therapeutics
![](https://cdn.snapi.dev/images/v1/p/r/press6-2216130.jpg)
Knight Therapeutics Announces Product Launch for IMVEXXY® in Canada
MONTREAL, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of IMVEXXY® in Canada....
Knight Therapeutics Inc. (KHTRF) Q3 2023 Earnings Call Transcript
Knight Therapeutics Inc. (OTCPK:KHTRF) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ETCompany ParticipantsSamira Sakhia - President and Chief...
Knight Therapeutics reports Q3 results
Knight Therapeutics reports Q3 earnings, with non-GAAP EPS of C$0.15 and revenue of C$0.08M.
![](https://cdn.snapi.dev/images/v1/o/c/press4-2149450.jpg)
Knight Therapeutics Reports Third Quarter 2023 Results
MONTREAL, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial r...
Notice of Knight Therapeutics’ Third Quarter 2023 Results Conference Call
MONTREAL, Nov. 02, 2023 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2023 financi...
![](https://cdn.snapi.dev/images/v1/c/0/conf9-2135702.jpg)
Notice of Knight Therapeutics' Third Quarter 2023 Results Conference Call
MONTREAL, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2023 financ...
Knight Therapeutics Inc. places No. 90 on The Globe and Mail’s fifth-annual ranking of Canada’s Top Growing Companies
MONTREAL, Oct. 02, 2023 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it placed No. 90 on the 2023 Report on Business ranking of Canada’s Top...
![](https://cdn.snapi.dev/images/v1/s/y/press15-2086668.jpg)
Knight Therapeutics Inc. places No. 90 on The Globe and Mail's fifth-annual ranking of Canada's Top Growing Companies
MONTREAL, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it placed No. 90 on the 2023 Report on Business ranking of Canada's To...
![](https://cdn.snapi.dev/images/v1/n/v/press15-2016863.jpg)
Knight Therapeutics Reports Second Quarter 2023 Results
MONTREAL, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial r...